Oct, 13 2016 18:15 JST

Source: Eisai

Eisai to Officially Launch "Chocola BB Rich Ceramide" in Stores Nationwide

Japan's First Food with Function Claims Drink Containing Ceramide
- "Drink" to Counter Dry Skin -

TOKYO, Oct, 13 2016 - (JCN Newswire) - Eisai Co., Ltd. announced today that it will launch its first food with function claims Chocola BB Rich Ceramide (Notification number: B60) in drugstores, pharmacies and convenience stores throughout Japan on Monday, October 17. The product is Japan's first drink that is a type of food with function claims containing glucosylceramide derived from rice.(1)

Ceramide is a component of the stratum corneum of the epidermis layer of human skin. Normally, ceramide fills the spaces between cells in the corneum of the skin, and plays a role in restraining the loss of moisture to the outside as well as protecting the skin from external stimuli such as ultraviolet rays. Therefore, a lack of ceramide advances transpiration of skin moisture, potentially leading to dryness in the skin. Since ceramide levels decline with age, it is important to appropriate replenish ceramide to counter dryness.

Containing glucosylceramide as its active component to make it harder for moisture to escape from the skin,(2) Chocola BB Rich Ceramide is a product that you can drink to counter dry skin. Furthermore, in addition to ceramide, the drink also contains collagen and hyaluronic acid which are known for their beauty properties, and is recommended for people who are highly beauty conscious. Chocola BB Rich Ceramide has a delicious, easy to drink pear flavor, is low in calories (8.2 kcal), and with zero caffeine, can be safely consumed before sleep.

Chocola BB Rich Ceramide is now available nationwide through a wide range of retail outlets including drug stores, pharmacies, convenience stores and Eisai's internet retailing site.

Centered around the signature OTC product Chocola BB Plus (Third-class OTC drug) for the relief of skin trouble, acne and mouth ulcers, Eisai has been expanding the Chocola BB brand to suit the needs and lifestyles of its customers such as Chocola BB Royal 2 (quasi-drug), a nutritional drink for invigoration when physically fatigued, Chocola BB Joma, a soft drink that contains vitamin B6 (Food with Nutrient Function Claims), and Chocola BB Mouth Ulcer Repair Shot (Third-class OTC drug), an oral care spray launched in August.

Through the Chocola BB brand, Eisai will continue to respond to the diverse needs of female consumers and support an ever-growing number of people to achieve health and beauty in their everyday lives.

(1) Chocola BB Rich Ceramide was accepted by the Consumer Affairs Agency as Japan's first food with functional claims drink that contains glucosylceramide derived from rice.

(2) For information such as the scientific basis of Chocola BB Rich Ceramide, please refer to the Consumer Affairs Agency's home page:
https://www.fld.caa.go.jp/caaks/cssc02/?recordSeq=41604270150104 (in Japanese only)


About Eisai
Eisai Co., Ltd. (TSE:4523; ADR:ESALY) is a research-based human health care (hhc) company that discovers, develops and markets products throughout the world. Eisai focuses its efforts in three therapeutic areas: integrative neuroscience, including neurology and psychiatric medicines; integrative oncology, which encompasses oncotherapy and supportive-care treatments; and vascular/immunological reaction. Through a global network of research facilities, manufacturing sites and marketing subsidiaries, Eisai actively participates in all aspects of the worldwide healthcare system. For more information about Eisai Co., Ltd., please visit www.eisai.com.


Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120
Source: Eisai
Sectors: BioTech

Copyright ©2018 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.

Related Press Release


Eisai to Present Latest Data on Perampanel and Rufinamide at Annual American Academy of Neurology Meeting
April 20 2018 17:50 JST
 
Eisai: World's First Bile Acid Transporter Inhibitor "GOOFICE 5mg Tablet" Launched in Japan
April 19 2018 11:07 JST
 
Eisai Enters Into Joint Research Agreement With the Broad Institute, Colorado State University, and University of Chicago
April 13 2018 13:22 JST
 
Eisai Submits Supplemental New Drug Application to U.S. FDA
April 02 2018 12:44 JST
 
Eisai and Nichi-Iko Pharmaceutical Enter Into Strategic Alliance Agreement
March 28 2018 18:33 JST
 
AbbVie and Eisai Obtain Additional Approval for New Indication of Fully Human Anti-TNF-alpha Monoclonal
March 23 2018 14:41 JST
 
Eisai: Anticancer Agent LENVIMA Approved for Additional Indication of Unresectable Hepatocellular Carcinoma (HCC) in Japan
March 23 2018 13:40 JST
 
Eisai Launches Gastrointestinal Prokinetic Agent Cidine (Cinitapride Hydrogen Tartrate) in China
March 14 2018 11:16 JST
 
Eisai and Merck & Co. Enter Global Strategic Oncology Collaboration for LENVIMA
March 08 2018 13:33 JST
 
Eisai and Purdue Pharma Announce Positive Topline Results From Key Clinical Studies of Lemborexant
March 08 2018 12:00 JST
 
More Press release >>

Latest Press Release


More Latest Release >>